India Pharma Outlook Team | Friday, 14 August 2026
Drug quality has become a bigger regulatory priority in India as authorities intensify inspections to strengthen manufacturing standards.
The latest signal comes from the Jammu and Kashmir and Ladakh High Court, which refused to quash proceedings against three directors of Corona Remedies over Locipil tablets classified as “Not of Standard Quality.”
The court linked access to safe medicines with the Article 21 right to life. The ruling comes alongside wider enforcement measures, including action against high-risk facilities, tighter state-level inspections and greater regulatory digitization.
Together, these measures show India’s growing focus on quality as a foundation for global pharmaceutical credibility.
The latest drug quality ruling concerns Locipil tablets manufactured by Corona Remedies in September 2015. Authorities collected a sample from ESIC Model Hospital in Bari Brahmana, Jammu. The Regional Drugs Testing Laboratory, Chandigarh, classified the sample as “Not of Standard Quality” on August 31, 2016.
Three company directors challenged the proceedings. They argued that technical personnel handled manufacturing operations and that they managed financial and policy matters. The High Court rejected the attempt to terminate the case at the threshold. It said evidence must establish the directors’ actual responsibility during trial.
The court also connected drug quality with the constitutional right to life under Article 21, reinforcing the public health importance of medicines meeting prescribed standards.
Also Read: How Can Indian Pharma Strengthen Quality Amid Rising FDA Scrutiny
India’s regulatory tightening extends well beyond individual court cases. A nationwide risk-based inspection campaign has produced action against approximately 860 of more than 960 high-risk pharmaceutical facilities. Authorities have used production stoppages, license suspensions and cancellations where inspections identified serious deficiencies.
Regulators now use factors such as compliance history, product recalls and patient risk to identify facilities for inspection. India has also pushed manufacturers toward WHO quality standards, strengthening the connection between domestic compliance and international expectations.
State-level action adds another layer to India’s drug quality framework. Maharashtra FDA inspected 434 Ayurvedic manufacturing establishments and issued show-cause notices to 135 manufacturers for violations. It permanently cancelled the licenses of 10 manufacturers after identifying serious deficiencies affecting medicine quality, safety and efficacy.
Meanwhile, regulatory discussions involving USFDA and Andhra Pradesh’s Drug Control Administration have focused on regulatory alignment, inspections, capacity building, training and compliance systems. Such cooperation helps pharma manufacturing clusters prepare for the expectations of highly regulated export markets.
These efforts matter because state regulators play a crucial role in licensing, inspections, testing and enforcement alongside the Central Drugs Standard Control Organization.
India is also using technology to strengthen drug quality control. CDSCO’s SUGAM platform provides online regulatory workflows, application tracking, approvals and industry information. The government has continued moving regulatory processes toward digital systems, while more than 99 per cent of CDSCO processes have been digitized, according to the Drugs Controller General of India.
Risk-based inspections and digital monitoring can give regulators better visibility across manufacturers, approvals and compliance histories. CDSCO also provides online access to approved drugs and manufacturing-related regulatory information.
The tightening of drug quality standards directly supports India’s ambition to remain the “Pharmacy of the World.” India supplies medicines to highly regulated markets, where manufacturers must meet stringent requirements from agencies such as the USFDA and European regulators.
Stronger inspections, WHO-aligned manufacturing practices, state-level enforcement, digital oversight and greater corporate accountability can reduce quality risks while improving confidence among international buyers. The approach also encourages Indian manufacturers to treat quality as an end-to-end responsibility spanning raw materials, production, testing, documentation and distribution.
India’s global pharmaceutical leadership therefore depends not only on manufacturing scale and competitive costs, but also on its ability to demonstrate consistent drug quality. The current regulatory push signals that India wants its “Pharmacy of the World” reputation to rest increasingly on quality, compliance and global standards, not volume alone.
